Arsenic Methylation and Lung and Bladder Cancer in a Case-control Study in Northern Chile

PMC full text:

Published in final edited form as:

Toxicol Appl Pharmacol. 2014 Jan 15; 274(2): 225–231.

Published online 2013 Dec 1. doi: 10.1016/j.taap.2013.11.014

Table 5

Lung and bladder cancer odds ratios (ORs) by tertile of %MMA in all subjects.^a

	Cases	Controls	Crude		Adjusted^b
	Cases	Controls	OR	95% CI	OR	95% CI
Lung cancer
Lower tertile	20	134	1.00	Ref	1.00	Ref
Medium tertile	29	117	1.66	0.89–3.09	1.91	0.99–3.67
Upper tertile	45	96	3.14	1.74–5.66	3.26	1.76–6.04
Continuous^c	94	347	1.11	1.06–1.17	1.11	1.05–1.17
Bladder cancer
Lower tertile	29	134	1.00	Ref	1.00	Ref
Medium tertile	46	117	1.82	1.07–3.08	1.81	1.06–3.11
Upper tertile	42	96	2.02	1.16–3.43	2.02	1.15–3.54
Continuous^c	117	347	1.05	1.00–1.10	1.04	1.00–1.09

^aThe upper and lower tertile cutoffs for %MMA are 12.5% and 8.5%, respectively.

^bOdds ratios adjusted for age, gender, and smoking.

^cLogistic regression entering %MMA as a continuous variable. The values given are the OR and its 95% CI for each 1% increase in %MMA.

Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference group; %MMA, the proportion of inorganic arsenic excreted in urine as MMA.